Sangamo Therapeutics (NASDAQ:SGMO) Stock Price Crosses Above Two Hundred Day Moving Average of $0.62

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $0.62 and traded as high as $0.67. Sangamo Therapeutics shares last traded at $0.67, with a volume of 1,254,967 shares changing hands.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on SGMO shares. StockNews.com started coverage on Sangamo Therapeutics in a report on Tuesday, February 13th. They set a "sell" rating on the stock. Royal Bank of Canada reissued a "sector perform" rating and set a $2.00 price objective on shares of Sangamo Therapeutics in a report on Thursday, March 14th. Finally, HC Wainwright reissued a "buy" rating and set a $5.00 price objective (up previously from $3.00) on shares of Sangamo Therapeutics in a report on Tuesday, March 19th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company. According to MarketBeat, Sangamo Therapeutics has an average rating of "Hold" and a consensus target price of $4.93.

Sangamo Therapeutics Stock Performance

The firm has a 50 day moving average of $0.80 and a two-hundred day moving average of $0.61. The stock has a market cap of $119.91 million, a P/E ratio of -0.46 and a beta of 1.44.

Institutional Trading of Sangamo Therapeutics

A number of hedge funds have recently modified their holdings of the company. BlackRock Inc. lifted its position in shares of Sangamo Therapeutics by 0.3% in the 2nd quarter. BlackRock Inc. now owns 15,888,976 shares of the biopharmaceutical company's stock worth $20,656,000 after acquiring an additional 48,282 shares during the period. Wasatch Advisors LP lifted its position in shares of Sangamo Therapeutics by 7.8% during the 1st quarter. Wasatch Advisors LP now owns 13,642,417 shares of the biopharmaceutical company's stock worth $24,011,000 after buying an additional 991,663 shares during the period. Vanguard Group Inc. lifted its position in shares of Sangamo Therapeutics by 10.5% during the 3rd quarter. Vanguard Group Inc. now owns 12,731,109 shares of the biopharmaceutical company's stock worth $62,383,000 after buying an additional 1,205,951 shares during the period. State Street Corp lifted its position in shares of Sangamo Therapeutics by 25.3% during the 1st quarter. State Street Corp now owns 7,775,327 shares of the biopharmaceutical company's stock worth $45,175,000 after buying an additional 1,570,740 shares during the period. Finally, Dimensional Fund Advisors LP lifted its position in shares of Sangamo Therapeutics by 12.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 3,444,283 shares of the biopharmaceutical company's stock worth $10,815,000 after buying an additional 373,442 shares during the period. Institutional investors own 56.93% of the company's stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.